In the quiet hum of a regional hospital laboratory in Saskatchewan, a medical technologist named Elena reviews a complex panel of genetic markers for a patient whose diagnosis has remained elusive for months. For Elena, the precision of her work represents the frontier of personalized medicine, where advanced testing can shift a patient’s trajectory from chronic uncertainty to targeted treatment. However, she also feels the pressure of resource constraints, balancing the high cost of specialized assays against the limited budget allocated by her provincial health authority.